Clinical Trial Update: Study of NG-641 in Combination With Nivolumab in Metastatic or Advanced Epithelial Tumours [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating NG-641 in combination with nivolumab for metastatic or advanced epithelial tumors has completed. The trial is sponsored by Akamis Bio…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Epithelial Tumor

Drugs mentioned

• NG-641
• nivolumab (nivolumab)

Snippet

Sponsor: Akamis Bio | Conditions: Metastatic Cancer, Epithelial Tumor | Phase 1 | Status: COMPLETED